References
- NICE. Clinical guideline 90: Depression in adults. The treatment and management of depression in adults [Internet]. London, UK: National Institute for Health and Care Excellence; 2009. http://guidance.nice.org.uk/CG90/Guidance/pdf/English. Accessed November 25, 2013
- Gayetot D, Ansseau M, Triffaux JM. [When depression does not end. Resistant depression: recent clinical and therapeutic aspects]. Rev Médicale Liège 2007;62:103-11
- Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol 2009;19:34-40
- Han C, Wang S-M, Kato M, et al. Second-generation antipsychotics in the treatment of major depressive disorder: current evidence. Expert Rev Neurother 2013;13:851-70
- Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163:1905-17
- Angst J, Angst F, Stassen HH. Suicide risk in patients with major depressive disorder. J Clin Psychiatry 1999;60(Suppl 2):57-62, discussion 75-6,113-16
- Mauskopf JA, Simon GE, Kalsekar A, et al. Nonresponse, partial response, and failure to achieve remission: humanistic and cost burden in major depressive disorder. Depress Anxiety 2009;26:83-97
- Byford S, Barrett B, Despiégel N, et al. Impact of treatment success on health service use and cost in depression: longitudinal database analysis. PharmacoEconomics 2011;29:157-70
- NICE. Clinical guideline 23: Depression: management of depression in primary and secondary care [Internet]. London, UK: National Institute for Health and Care Excellence; 2004. http://www.nice.org.uk/guidance/index.jsp?action=byID&o=10958. Accessed April 2, 2014
- Joint Formulary Committee. British National Formulary (BNF) 69. 69th ed. London and Chicago: Pharmaceutical Press; 2015. 1164 p
- Wang P, Si T. Use of antipsychotics in the treatment of depressive disorders. Shanghai Arch Psychiatry 2013;25:134-40
- Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004;161:414-25
- Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009;166:980-91
- Janicak PG, Martis B. Strategies for treatment-resistant depression. Clin Cornerstone 1999;1:58-71
- Classi P, Ball S, Davé S, et al. Adjunctive pharmacotherapy and treatment patterns among initiators of SSRI therapy for major depressive disorder: A cohort study using a primary care database. Open J Psychiatry 2012;2:211-19
- Lamy FX, Chollet J, Clay E, et al. Pharmacotherapeutic strategies for patients treated for depression in UK primary care: a database analysis. Curr Med Res Opin 2015;31:795-807
- Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol 2015;44:827-36
- García Rodríguez LA, Pérez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998;45:419-25
- Herrett E, Thomas SL, Schoonen WM, et al. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010;69:4-14
- Nazareth I, King M, Haines A, et al. Accuracy of diagnosis of psychosis on general practice computer system. BMJ 1993;307:32-4
- Thomas KH, Davies N, Metcalfe C, et al. Validation of suicide and self-harm records in the Clinical Practice Research Datalink. Br J Clin Pharmacol 2013;76:145-57
- Alonso J, Angermeyer MC, Bernert S, et al. Psychotropic drug utilization in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 2004;420:55-64
- Luca M, Prossimo G, Messina V, et al. Epidemiology and treatment of mood disorders in a day hospital setting from 1996 to 2007: an Italian study. Neuropsychiatr Dis Treat 2013;9:169-76
- Konstantinidis A, Papageorgiou K, Grohmann R, et al. Increase of antipsychotic medication in depressive inpatients from 2000 to 2007: results from the AMSP International Pharmacovigilance Program. Int J Neuropsychopharmacol Off Sci J Coll Int Neuropsychopharmacol CINP 2012;15:449-57
- Boonstra G, Grobbee DE, Hak E, et al. Initiation of antipsychotic treatment by general practitioners. a case-control study. J Eval Clin Pract 2011;17:12-17
- Trifirò G, Spina E, Brignoli O, et al. Antipsychotic prescribing pattern among Italian general practitioners: a population-based study during the years 1999–2002. Eur J Clin Pharmacol 2005;61:47-53